Starwatch: Mars and Regulus will make for an eye-catching pair
Look into the western sky this week to see an eye-catching conjunction between Mars and Regulus, the brightest star in the constellation of Leo, the lion. The chart shows the view from London at 2300 BST on 16 June 2025.
The pair of celestial objects will be separated by less than a degree, less than twice the apparent diameter of the full moon. This means that as well as being an easy spot with the naked eye, they are close enough to fit into the same field of view when viewed through binoculars. Although they will move further apart as the week continues.
The colour difference between them will be striking. Mars will be red whereas Regulus shines with a blue-white colour. Regulus is the 21st brightest star in the night sky and lies about 79 light years away from us. It contains just over four times the mass of the sun, and has a diameter just over four times larger, too, giving out about 340 times the sun's energy.
From the southern hemisphere, too, the conjunction appears in the north-north-west. In addition, on 19 June, the moon will be close to Saturn in the constellation Pisces, the fishes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
14 minutes ago
- BBC News
Southampton pancreatic cancer blood test trial seeks patients
A programme to evaluate a blood test for early signs of pancreatic cancer has started to recruit Safe-D study, based in Southampton, Hampshire, is signing up patients with type 2 diabetes, which is a known risk factor for the blood test is reported to be 68% accurate in detecting pancreatic cancer markers, according to initial disease often has vague symptoms and can lead to death within months of diagnosis. Sean Cleghorn's wife, Allison, discovered she had pancreatic cancer at Christmas in 2020 and died four weeks later at the age of father of three, from Kingsclere, Hampshire, said: "The only symptom Allison displayed was some slight indigestion and then she was diagnosed with type 2 diabetes in the autumn of 2020."Allison had always eaten healthily, was active and avoided processed food, so this diagnosis was puzzling for us. Mr Cleghorn added: "When we learned that new-onset type 2 diabetes was a potential risk factor for pancreatic cancer, we asked for further testing and a scan confirmed she had terminal cancer."Perhaps if she had been diagnosed sooner with a test like the one that's currently being trialled, we may have had time to make more memories with our three children."The Avantect blood test will be evaluated at the Cancer Research UK Southampton Clinical Trials recruits will have blood samples tested to help design the main surgeon Zaed Hamady who is leading the study said: "Although most people with diabetes will not go on to develop the disease, new onset diabetes is associated with a six- to eight-fold increased risk."This patient group gives us a way to test how accurate the new diagnostic blood test is."Previously, researchers have claimed successes for pancreatic cancer tests involving urine samples and nematode no test is reliable and accurate enough for a national screening programme, according to the charity Pancreatic Cancer UK. You can follow BBC Hampshire & Isle of Wight on Facebook, X (Twitter), or Instagram.
Daily Mail
an hour ago
- Daily Mail
Could Putin attack Britain by blocking the SUN? Fears hostile actors might deploy 'weather weapons' as ministers order probe into 'risks'
Foreign states could 'create chaos' by dimming Britain's sun and orchestrating a natural disaster, ministers have been warned. There are fears hostile actors such as Russia could make use of solar engineering technology to reflect light away from the earth and back into space. The concept - using techniques such as deploying aerosols into the atmosphere to reflect light back into space - has been mooted as a way of limiting global warming. However, experts say that comes with major risks - and concerns have been raised within government that it could be abused by 'an independent or third-party actor'. Net Zero minister Kerry McCarthy wrote in a letter: 'The UK is a longstanding leader on climate action and an active international collaborator in scientific research. 'The Government recognises the need to understand the risks and impacts of [solar radiation modification] approaches that could be deployed by an independent or third-party actor.' In the letter seen by The Telegraph, she added: 'Robust scientific evidence is essential for informing responsible and inclusive governance.' Aria - the government's advanced research and invention agency - has allocated £50million in funding for outdoor field trials, which include brightening clouds to reflect sunshine Matt Ince, associate director at Dragonfly Intelligence, said Vladimir Putin's Russia was 'increasingly expanding its use of hybrid warfare activities'. He cautioned geoengineering may be seen as a desirable option due to its 'relative affordability' and the 'feasibility of conducting it' and added some sort of intentionally orchestrated environmental disaster' is an 'avenue that Russia may pursue'. Such tactics could 'create chaos and a sense of discord, and force countries to become more inward focussed'. It comes as more than 560 academics have signed an open letter calling for an 'international non-use agreement' on solar geoenginering. The letter states that without the limits the resulting geopolitics could be 'frightening and inequitable'. Aria - the government's advanced research and invention agency - has allocated £50million in funding for outdoor field trials, which include brightening clouds to reflect sunshine. However, the government is not proposing to deploy it for 'climate cooling'. An Aria spokesman said: 'In line with the Government's position on SRM deployment, Aria is not funding deployment, and does not support, the deployment of any climate cooling approaches.' The agency aims to 'unlock scientific and technological breakthroughs that benefit everyone'. 'We empower scientists and engineers to pursue research that is too speculative, too hard, or too interdisciplinary to pursue elsewhere,' it says on its website. The research agency was originally the brainchild of Dominic Cummings, Boris Johnson's former chief aide, and was set up in 2021 by ex-Tory business secretary Kwasi Kwarteng. The body, based in London, has been given a staggering £800million budget – of taxpayers' cash – to go towards 'high-risk, high-reward' scientific research. A Government spokesman said: 'The government is not in favour of using solar radiation modification, but we support cautious, controlled research aimed at improving our understanding of its risks and impacts.
The Sun
2 hours ago
- The Sun
Blood test to detect early signs of deadliest cancer trialled in UK – and doctors are calling for people to take part
A NEW blood test to pick up early signs of a cancer which kills more than half of people within three months of diagnosis is being trialled by UK doctors. The genomic test uses blood samples to look for markers of the deadly disease, which often has vague symptoms. 2 Currently, the UK doesn't have a national screening programme for pancreatic cancer like it does for breast or bowel cancer. A huge issue is the disease is often diagnosed at a late stage because it frequently lacks noticeable symptoms in the early stages. But a new pancreatic cancer test is being trialled in patients with a recent diagnosis of type 2 diabetes - a known risk factor for the disease. People over 50 with a new case of type 2 diabetes have a higher chance of also being diagnosed with pancreatic cancer within three years. Early data suggests the Avantect test is 68 per cent accurate in picking up people with early stages of the disease, which kills almost 10,000 people every year in the UK. It's also 97 per cent accurate in ruling out people without pancreatic cancer. The new clinical trial has been launched at the Cancer Research UK Southampton Clinical Trials Unit. Zaed Hamady, consultant surgeon and pancreatic researcher at the University of Southampton, who's leading the trial, said: "There is currently no targeted early detection or surveillance test for the disease meaning patients are often diagnosed late when they become really unwell. "If we can develop approaches to detect the cancer sooner, then there are more options we may consider to treat the disease, and patients will have a much better chance of long-term survival. "Although most people with diabetes will not go on to develop the disease, new onset diabetes is associated with a six to eight-fold increased risk. "This patient group gives us a way to test how accurate the new diagnostic blood test is, and that could potentially help thousands of people in the future." According to researchers, newly-diagnosed type 2 diabetes patients often have similar symptoms as a person with early-stage pancreatic cancer. This is because the cancer destroys the same insulin-producing cells that are also destroyed in diabetes. 'Earlier diagnosis would have meant time to make more memories with our children' Sean Cleghorn's wife, Allison, discovered she had pancreatic cancer at Christmas 2020 but died four weeks later aged 54. Mr Cleghorn, a father of three from Kingsclere in Hampshire, said: "The only symptom Allison displayed was some slight indigestion and then she was diagnosed with type 2 diabetes in the autumn of 2020. "Allison had always eaten healthily, was active and avoided processed food, so this diagnosis was puzzling for us. "When we learned that new-onset type 2 diabetes was a potential risk factor for pancreatic cancer, we asked for further testing and a scan confirmed she had terminal cancer. "We hoped she could have chemotherapy to prolong her life, but she became too weak and died four weeks later. "Perhaps if she had been diagnosed sooner with a test like the one that's currently being trialled, we may have had time to make more memories with our three children." Angelica Cazaly, senior trial manager for the trial, said: "We are asking people with newly diagnosed type 2 diabetes who are attending GP surgeries or diabetic clinics whether they would like to take part in the study. "Initially, we will collect blood samples from 800 people for testing. "The results from the test, together with medical information collected from each patient, will help provide researchers with important information on how best to proceed with the rest of the study that will evaluate how accurate the test is at predicting pancreatic cancer." 'Exciting time for early detection research' 2 Around 10,500 people in the UK are diagnosed with pancreatic cancer every year and just one in 20 survive the disease for 10 years or more. Samuel Levy, chief scientific officer of ClearNote Health, said: "Our early data demonstrate that our Avantect test can identify pancreatic cancer in stages I and II. "We are excited to collaborate with the Cancer Research UK Southampton Clinical Trials Unit and the University Hospital Southampton NHS Foundation Trust on this transformative study that could redefine how pancreatic cancer is detected and managed for patients at high risk." Dr Chris Macdonald, head of research at Pancreatic Cancer UK, said over 80 per cent of people with pancreatic cancer are currently diagnosed too late for treatment. He added: "This is an exciting time for early detection research, with tests using blood, breath and urine in development which, if shown to be successful in clinical trials, could save thousands of lives every year. "Early findings from these tests are very promising, but more research is needed to ensure that they are as accurate as possible before they will be available in the GP surgery."
